304 related articles for article (PubMed ID: 29962813)
21. Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges.
Soriano V; Tefferi A
Cancer; 2018 Apr; 124(8):1647-1649. PubMed ID: 29486060
[No Abstract] [Full Text] [Related]
22. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
[TBL] [Abstract][Full Text] [Related]
23. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
24. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
Weiler N; Zeuzem S; Welker MW
World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
[TBL] [Abstract][Full Text] [Related]
25. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
26. Development of novel treatments for hepatitis C.
Webster DP; Klenerman P; Collier J; Jeffery KJ
Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
Poynard T; Ngo Y; Munteanu M; Thabut D; Massard J; Moussalli J; Varaud A; Benhamou Y; Ratziu V
Antivir Ther; 2010; 15(4):617-31. PubMed ID: 20587855
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic update in hepatitis C].
Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
[TBL] [Abstract][Full Text] [Related]
29. Complexities of HCV management in the new era of direct-acting antiviral agents.
Rosenberg WM; Tanwar S; Trembling P
QJM; 2014 Jan; 107(1):17-9. PubMed ID: 24065837
[TBL] [Abstract][Full Text] [Related]
30. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings.
Guss D; Sherigar J; Rosen P; Mohanty SR
J Gen Intern Med; 2018 Apr; 33(4):551-557. PubMed ID: 29352420
[TBL] [Abstract][Full Text] [Related]
32. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
[TBL] [Abstract][Full Text] [Related]
33. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
Ueda Y; Uemoto S
Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
[TBL] [Abstract][Full Text] [Related]
35. Management of hepatitis C infection among patients with renal failure.
Latt NL; Araz F; Alachkar N; Durand CM; Gurakar A
Minerva Gastroenterol Dietol; 2015 Mar; 61(1):39-49. PubMed ID: 25390288
[TBL] [Abstract][Full Text] [Related]
36. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
37. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
Sorbera MA; Friedman ML; Cope R
J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
[TBL] [Abstract][Full Text] [Related]
38. Direct-acting agents for hepatitis C virus before and after liver transplantation.
Sugawara Y; Hibi T
Biosci Trends; 2018 Jan; 11(6):606-611. PubMed ID: 29238003
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Dhersin JS; Yazdanpanah Y
Hepatology; 2016 Apr; 63(4):1090-101. PubMed ID: 26390137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
